Alnylam Pharmaceuticals, Inc.

Amvuttra

Manufacturer:

Alnylam Pharmaceuticals, Inc.

Amvuttra HCPCS:

J0225

HCPCS Code Descriptor:

Injection, vutrisiran, 1 mg

Category:

J Code

Amvuttra NDCs:

71336-1003-01

Primary Type:

Genetic Disorder

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Amvuttra:

Amvuttra is a Genetic Disorder drug manufactured by Alnylam Pharmaceuticals, Inc. and administered via the Subcutaneous route of administration. The J Code: J0225 is aligned to the drug Amvuttra.

ACCESS PRICING AND MORE BY REGISTERING

J0225 Added Date:

January 1, 2023

J0225 Effective Date:

January 1, 2023

J0225 Termination Date:

HCPCS Active

Amvuttra billing and coding information can be found through Alnylam Pharmaceuticals, Inc. at the link below:
Amvuttra patient assistance information can be found through Alnylam Assist at the URL: https://www.alnylamassist.com/
Amvuttra prescribing information can be found at the link below:
Information regarding Amvuttra’s side effects can be found at MedlinePlus